Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Poolbeg Pharma (LSE:POLB): Clinical and Partnering Catalysts Keep This FTSE AIM All-Share Small-Cap Growth Stock on Watch

• The next major catalyst is clinical milestones, partnering, trial data, funding runway and portfolio prioritisation.

Ankur Sharma | 16 November 2026

Proteome Sciences (LSE:PRM): Chemoproteomics Contracts Put This FTSE AIM All-Share Small-Cap Growth Stock Back on Watch

• The next major catalyst is contract pipeline, recurring services, margins,Cash Flowand pharma demand.

Ankur Sharma | 16 November 2026

Provexis (LSE:PXS): Volatile Trading Keeps This FTSE AIM All-Share Small-Cap Growth Stock on the Healthcare Radar

• The next major catalyst is commercial progress, licensing or partner activity, cash generation and product traction.

Ankur Sharma | 16 November 2026

Surgical Innovations (LSE:SUN): APAC Momentum and Margin Recovery Put This FTSE AIM All-Share Small-Cap Growth Stock on Watch

• The next major catalyst is H2 sales, margin recovery, APAC momentum, OEMDemandand balance-sheet discipline.

Ankur Sharma | 16 November 2026

CVS Group Puts Veterinary Care and Pet Ownership Trends in the Spotlight (LSE:CVSG)

The 1.06% advance reflects a firmer share price in this session. It does not establish that a particular company announcement caused the gain. The more useful lens is how consultation volumes, pricing and clinical capacity combine to shapeEarningsand cash generation.

Ankur Sharma | 16 November 2026

FTSE SmallCap Small Cap Growth: Biotech Growth Trust plc (LSE:BIOG) — A Large Buyback Programme Adds a New Catalyst to the Biotech Trust

• The main focus is onEarningsquality, cash flow, balance-sheet strength and strategic execution.

Ankur Sharma | 16 November 2026

How Thalia Therapeutics PLC (LSE:THAT) Evaluates Preclinical Orphan Drug Designation Pathways Across European Regulators

The core focus of Thalia's scientific team centres on validating lead small-molecule candidates engineered to modulate specific intracellular enzymatic pathways implicated in rare metabolic storage diseases. Preclinical pharmacodynamic studies conducted in collaboration with leading academic medical institutions have confirmed target engagement and favourable safety …

Ankur Sharma | 16 November 2026

Why TSP Advanced Technologies plc (LSE:TSP) Outlines Its Path to Annual Financial Reporting

Trading in the ordinary shares of TSP Advanced Technologies (LSE:TSP) on the Aquis Stock Exchange Growth Market has been paused since the start of trading on 1 October 2026 under Rule 5.1 of the AQSE Growth Market Access Rulebook, while the audited annual accounts …

Ankur Sharma | 16 November 2026

How Tristel Plc (LSE:TSTL) Validates Chlorine Dioxide Foam Contact Times for Semi-Critical Medical Probes in the FTSE AIM All-Share

A transformative growth catalyst for Tristel is the ongoing commercial rollout of its Tristel ULT ultrasound decontamination platform in the United States healthcare market. Following landmark regulatory approvals from the US Food and Drug Administration (FDA), Tristel entered into an exclusive nationwideManufacturingand commercial distribution …

Ankur Sharma | 16 November 2026

What ValiRx PLC (LSE:VAL) Disclosed Concerning Cytotoxicity Assay Throughput at Inaphaea BioLabs in the FTSE AIM All-Share

A cornerstone of ValiRx's revised business architecture is Inaphaea BioLabs, a wholly owned contract laboratory servicesSubsidiaryoperating from laboratory facilities in Nottingham. Inaphaea provides specialized cell-based assay services, patient-derived tissue profiling, and drug screening capabilities. In addition to conducting internal preclinical evaluations for ValiRx's proprietary …

Ankur Sharma | 16 November 2026
Support

Hi! How can we help you today?

Loading…